• In January 2026, Establishment Labs Holdings Inc. reported preliminary unaudited revenue guidance for the fourth quarter of 2025 of US$64.0 million to US$65.0 million, including US$17.0 million to US$17.5 million from Motiva sales in the United States.
• For full-year 2025, the company expects US$210.5 million to US$211.5 million in revenue, with Motiva’s United States contribution highlighting the growing importance of that market within its overall sales mix.
• We’ll examine how this preliminary revenue guidance, particularly the growing Motiva contribution from the United States, shapes Establishment Labs’ investment narrative.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

What Is Establishment Labs Holdings' Investment Narrative?

To own Establishment Labs, you need to believe that its Motiva platform can scale globally while the business transitions from high-growth, high-spend to something closer to self-sustaining. The latest preliminary 2025 revenue guidance, at about US$210.5 million to US$211.5 million with roughly US$45 million from Motiva in the US, reinforces the idea that the US is becoming a more meaningful part of the story rather than just an option on future growth. In the near term, that supports key catalysts around US adoption and clinical data for Motiva and Mia Femtech, but it does not resolve the core issues of ongoing losses, a very large negative return on equity and a limited cash runway under an expensive Oaktree facility. The guidance looks supportive, yet financial risk still feels front and center.

However, the company’s limited cash runway and leverage are risks investors should not overlook. Establishment Labs Holdings' share price has been on the slide but might be up to 9% below fair value. Find out if it's a bargain.

Exploring Other Perspectives

Three Simply Wall St Community fair value views cluster between about US$60.63 and US$79.67, reflecting very different expectations. Set those against the recent revenue guidance uplift and ongoing losses, and you can see why opinions about Establishment Labs’ future are so varied.

Explore 3 other fair value estimates on Establishment Labs Holdings - why the stock might be worth as much as 21% more than the current price!

Build Your Own Establishment Labs Holdings Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Establishment Labs Holdings research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Establishment Labs Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Establishment Labs Holdings' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.